This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes	Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2)	<p>Mouse studies suggest inhibiting CITED2 could help treat diabetic hyperglycemia. In obese diabetic mice, small hairpin RNA against Cited2 decreased both gluconeogenic gene expression and blood glucose compared with control shRNA. Next steps include identifying small molecules that lower CITED2 expression.</p> <p>SciBX 5(14); doi:10.1038/scibx.2012.369 Published online April 5, 2012</p>	Findings unpatented; licensing status unavailable	<p>Sakai, M. <i>et al. Nat. Med.</i>; published online March 18, 2012; doi:10.1038/nm.2691</p> <p>Contact: Masato Kasuga, National Center for Global Health and Medicine, Tokyo, Japan e-mail: kasuga@ri.ncgm.go.jp</p> <p>Contact: Michihiro Matsumoto, same affiliation as above e-mail: mmatsumoto@ri.ncgm.go.jp</p>